| REVIEW ARTICLE |
|
| Year : 2015 | Volume
: 7
| Issue : 3 | Page : 81-85 |
|
|
Clinical use of insulin degludec: Practical experience and pragmatic suggestions
Sanjay Kalra1, Yashdeep Gupta2
1 Consultant (Endocrinology and Metabolism), Bharti Hospital, Karnal, Haryana, India
2 Department of Medicine, Government Medical College and Hospital, Chandigarh, India
Correspondence Address:
Sanjay Kalra
DM Endocrinology, Consultant (Endocrinology and Metabolism), Bharti Hospital, Kunjpura Road, Karnal - 132 001, Haryana
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1947-2714.153918
|
|
|
Insulin degludec (IDeg) is an ultralong acting basal insulin. IDeg has unique pharmacokinetic and pharmacodynamic properties which allow once a daily dosage, at any time of the day. Its use is associated with a significantly lower risk of hypoglycemia. This review discusses the pragmatic use of IDeg, based on available evidence. A complete search of all nine original research papers (BEGIN® clinical trial program) pertaining to IDeg, listed in PubMed, was made to prepare this article. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
